Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 25 Sep 2026
₹1,668.4
Change
+43.6 (2.68%)
Open
₹1,618.0
Prev. Close
₹1,624.8
Day High
₹1,705.0
Day Low
₹1,611.9
Volume Analysis
Traded
36,028
Delivered
22,292
Delivery %
61.87%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (57.0%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,804.74 | ₹1,754.87 | ₹1,711.64 | ₹1,661.77 | ₹1,618.54 | ₹1,568.67 | ₹1,525.44 |
| Fibonacci | ₹1,754.87 | ₹1,719.31 | ₹1,697.33 | ₹1,661.77 | ₹1,626.21 | ₹1,604.23 | ₹1,568.67 |
| Camarilla | ₹1,694.0 | ₹1,685.47 | ₹1,676.93 | ₹1,661.77 | ₹1,659.87 | ₹1,651.33 | ₹1,642.8 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+119.38%
1 Week
+4.72%
1 Month
+2.56%
3 Months
-9.0%
6 Months
+93.76%
1 Year
+279.7%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹927.33
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.6%
Net margin 14.3% × asset turnover 0.9x × equity multiplier 1.29x
Company Overview
Sector
Healthcare
Market Cap
₹2,230 Cr
P/E (TTM)
19.2
ROE
16.8%
Book Value
₹497.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Venus Remedies Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 71/100. The strongest factor is Financial Strength (100/100), while Risk & Volatility (49/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%). Strong 3-year EPS growth (57.0%).
TopFund Score — Fundamentals Quality
71/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has delivered good profit growth of 21.8% CAGR over last 5 years
- −Stock is trading at 3.36 times its book value
- −The company has delivered a poor sales growth of 7.18% over past five years.
- −Company has a low return on equity of 10.5% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Newspaper publication of shareholder notice on Transfer of physical shares.
Newspaper publication for shareholders awareness on transfer of physical shares.
Social media notice on special window for re-lodgement of physical share transfer requests.
37th AGM resolutions passed, including Rs.10 final dividend and director appointments.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 95 | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 |
| Expenses + | 85 | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 |
| Operating Profit | 10 | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 |
| OPM % | 11.0% | 11.0% | 8.0% | 10.0% | 10.0% | 4.5% | 10.0% | 15.0% | 11.0% | 16.0% | 21.0% | 24.0% | 19.0% |
| Other Income + | 2 | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 |
| Profit before tax | 5 | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Tax % | 77.0% | 31.0% | 12.0% | 40.0% | 82.0% | 61.0% | 21.0% | 32.0% | 24.0% | 24.0% | 24.0% | 23.0% | 24.0% |
| Net Profit + | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 |
| EPS in Rs | 1 | 7 | 5 | 8 | 1 | 3 | 15 | 16 | 7 | 15 | 19 | 36 | 17 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 455 | 407 | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 640 | 770 | 811 |
| Expenses + | 366 | 326 | 349 | 333 | 289 | 295 | 490 | 535 | 492 | 537 | 577 | 622 | 645 |
| Operating Profit | 89 | 81 | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 64 | 147 | 166 |
| OPM % | 20.0% | 20.0% | 13.0% | 11.0% | 10.0% | 12.0% | 10.0% | 10.0% | 11.0% | 10.0% | 10.0% | 19.0% | 20.0% |
| Other Income + | 1 | 2 | 2 | 2 | -3 | -4 | 43 | 8 | 10 | 12 | 31 | 13 | 12 |
| Interest | 41 | 38 | 34 | 35 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 26 | 26 |
| Profit before tax | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 134 | 152 |
| Tax % | -95.0% | 52.0% | -21.0% | 11.0% | -4.0% | 24.0% | -27.0% | -12.0% | 30.0% | 36.0% | 37.0% | 23.0% | — |
| Net Profit + | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 103 | 116 |
| EPS in Rs | 5 | 1 | -14 | -25 | -23 | -8 | 50 | 30 | 20 | 21 | 34 | 77 | 87 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 13.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 445 | 426 | 376 | 350 | 320 | 311 | 388 | 427 | 447 | 474 | 548 | 650 |
| Borrowings + | 321 | 335 | 312 | 307 | 298 | 220 | 51 | 43 | 42 | 41 | 2 | 12 |
| Other Liabilities + | 64 | 70 | 65 | 82 | 102 | 100 | 104 | 97 | 98 | 98 | 153 | 178 |
| Total Liabilities | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
| Fixed Assets + | 444 | 452 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 232 |
| CWIP | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 51 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 238 |
| Other Assets + | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 | 333 |
| Total Assets | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
| Equity Capital | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 | 156 |
| Cash from Investing Activity + | -67 | 3 | -18 | 8 | -11 | -5 | 57 | -17 | -58 | -8 | -77 | -182 |
| Cash from Financing Activity + | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | -1 | -3 |
| Net Cash Flow | -1 | 3 | -4 | 0 | -1 | 0 | 27 | 14 | -22 | 28 | 9 | -29 |
| CFO/OP | 76 | 58 | 116 | 79 | 139 | 190 | 245 | 66 | 61 | 89 | 160 | 129 |
| Free Cash Flow | 59 | 46 | 41 | 19 | 35 | 70 | 132 | 41 | 29 | 24 | 69 | 118 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 57.21% | 56.65% | 56.76% | 57.17% | 57.06% | 57.13% | 56.9% | 55.89% | 55.62% | 54.95% | 54.24% | 54.44% |
| Promoters | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FII | 1.03% | 1.59% | 1.48% | 1.06% | 1.18% | 1.11% | 1.34% | 2.25% | 1.86% | 2.25% | 2.8% | 2.92% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.11% | 0.75% | 1.03% | 1.2% | 0.89% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Venus Remedies Limited (this stock) | 2,230 | 19.2 | 3.36 | 16.8% |
| Sai Parenterals Limited | 2,226 | 107.0 | — | 4.88% |
| Windlas Biotech Limited | 2,274 | 34.2 | 4.01 | 12.2% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
| Fredun Pharmaceuticals L | 2,305 | 52.6 | 8.2 | 15.6% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
| Beta Drugs Limited | 2,400 | 52.6 | 8.98 | 18.8% |
Which Mutual Funds Hold Venus Remedies Limited?
Frequently Asked Questions about Venus Remedies Limited
Venus Remedies Limited (VENUSREM) closed at ₹1,668.4 on NSE on 25 September 2026, up 43.6 (2.68%) from the previous close.
Venus Remedies Limited trades on the NSE (National Stock Exchange of India) under the symbol VENUSREM.
Venus Remedies Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 19.2.
Venus Remedies Limited has a dividend yield of 0.6%.
Venus Remedies Limited's 52-week high is ₹2,044.0 and its 52-week low is ₹424.0.
Venus Remedies Limited has a market capitalisation of ₹2,230 crore.
Venus Remedies Limited has a TopFund Quality Score of 71/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Venus Remedies Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.